What question did this study set out to answer?

To explore innovative treatment strategies for chronic lymphocytic leukemia and small lymphocytic leukemia.

April 23, 2026

Studies continue to individualize treatment strategies for patients with CLL and SLL

Key Points

To explore innovative treatment strategies for chronic lymphocytic leukemia and small lymphocytic leukemia.
Trial data analysis on pirtobrutinib for first-line treatment in chronic lymphocytic leukemia.
FDA approval process overview for pembrolizumab and enfortumab vedotin.
Review of breast cancer screening methods comparing risk-based to annual screening.
Pirtobrutinib significantly improves progression-free survival in untreated patients with chronic lymphocytic leukemia.
FDA approved a combination treatment for muscle-invasive bladder cancer.
Risk-based breast cancer screening was found to be noninferior to traditional annual screening.

Abstract

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, trial data show that first‐line pirtobrutinib significantly improves progression‐free survival in patients with previously untreated chronic or small lymphocytic leukemia. In addition, the FDA approves perioperative pembrolizumab plus enfortumab vedotin for cisplatin‐ineligible muscle‐invasive bladder cancer, and a trial shows that risk‐based breast cancer screening is noninferior to annual screening.

AI से पूछें

Bookmark